The Relationship between Diffuse Axonal Damage and Fatigue in Multiple Sclerosis

Archives of Neurology

Volumn 61, Issue 2, 2004, Pages 201-207

  Tartaglia, Maria Carmela ^a   Narayanan, Sridar ^a   Francis, Simon J ^a   Santos, Antonio Carlos ^a   De Stefano, Nicola ^b   Lapierre, Yves ^a   Arnold, Douglas L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; DIFFUSE AXONAL INJURY; DISABILITY; DISEASE DURATION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FATIGUE SEVERITY SCALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUESTIONNAIRE; RATING SCALE; RISK FACTOR; SYMPTOM;

ADULT; ASPARTIC ACID; AXONS; BRAIN CHEMISTRY; CREATINE; CROSS-SECTIONAL STUDIES; FATIGUE; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES;

EID: 1042302761     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.2.201     Document Type: Article

References (73)

1. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994;21:9-14.
2. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(suppl 1):S79-S83.
3. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121-1123.
4. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res. 1993;37:753-762.
5. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci. 2002;205:51-58.
6. Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol 1988;45:435-437.
7. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil. 1984;65:135-138.
8. Giesser B. Multiple sclerosis: current concepts in management. Drugs 1985;29:88-95.
9. Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler. 2000;6:181-185.
10. Guidelines MSCfCP. Fatigue and Multiple Sclerosis: Evidence-Based Strategies for Fatigue in Multiple Sclerosis. Washington, DC: Paralyzed Veterans of America; 1998.
11. The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci. 1987;14:273-278.
12. Sandroni P, Walker C, Starr A. "Fatigue" in patients with multiple sclerosis: motor pathway conduction and event-related potentials. Arch Neurol. 1992;49:517-524.
13. Rolak. Fatigue and multiple sclerosis. In: Dawson DM, Sabin T, ed; Chronic Fatigue Syndrome. Boston, Mass: Little Brown and Co; 1983;153-160:160.
14. Patten BM, Hart A, Lovelace R. Multiple sclerosis associated with defects in neuromuscular transmission. J Neurol Neurosurg Psychiatry. 1972;35:385-394.
15. Olgiati R, Burgunder JM, Mumenthaler M. Increased energy cost of walking in multiple sclerosis: effect of spasticity, ataxia, and weakness. Arch Phys Med Rehabil. 1988;69:846-849.
16. Colombo B, Boneschi FM, Rossi P, et al. MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. J Neurol. 2000;247:506-509.
17. Roelcke U, Kappos L, Lechner-Scott J, et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue 18F-fluorodeoxyglucose positron emission tomography study. Neurology. 1997;48:1566-1571.
18. Roelcke U. Pathophysiology of fatigue in multiple sclerosis. In: Kappos L KJ, Radu EW, Johnson K, eds; Multiple Sclerosis Tissue Destruction and Repair. London, England: Martin Dunitz Ltd; 2001:171-176.
19. Leocani L, Colombo B, Magnani G, et al. Fatigue in multiple sclerosis is associated with abnormal cortical activation to voluntary movement - EEG evidence. Neuroimage. 2001;13:1186-1192.
20. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 1994;117:49-58.
21. Davie CA, Barker GJ, Thompson AJ, Tofts PS, McDonald WI, Miller DH. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;63:736-742.
22. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain. 1998;121:103-113.
23. Matthews PM, Arnold DL. Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution. Curr Opin Neurol. 2001;14:279-287.
24. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001;58:65-70.
25. Arnold DL, Matthews PM, Francis GS, O'Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol. 1992;31:235-241.
26. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med. 1990;14:154-159.
27. Matthews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis [published erratum appears in Neurology. 1991;41:1828]. Neurology. 1991;41:1251-1256.
28. Matthews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis [published erratum appears in Neurology. 1991;41:1828]. Neurology. 1991;41:1251-1256.
29. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain. 1998;121:3-24.
30. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285.
31. Richards TL. Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy. AJR Am J Roentgenol. 1991;157:1073-1078.
32. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience. 1991;45:37-45.
33. Bergamaschi R, Romani A, Versino M, Poli R, Cosi V. Clinical aspects of fatigue in multiple sclerosis. Funct Neurol. 1997;12:247-251.
34. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995;45:1956-1961.
35. Bakshi R, Miletich RS, Henschel K, et al. Fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients. Neurology. 1999;53:1151-1153.
36. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
37. Ordidge RJ, Mansfield P, Lohman JA, Prime SB. Volume selection using gradients and selective pulses. Ann N Y Acad Sci. 1987;508:376-385.
38. den Hollander JA OB, van Vroonhoven H, Luyten PR. Elimination of magnetic field distortions in 1H NMR spectroscopic imaging [abstract]. Proc Soc Magn Reson Med. 1991;1:472.
39. Arnold D, Narayanan S, De Stefano N, Reddy H, Matthews PM. Magnetic resonance spectroscopy of multiple sclerosis: imaging axonal damage. In: Kappos L, Kesselring, Radu EW, Johnson, eds; Multiple Sclerosis: Tissue Destruction and Repair. London, England: Martin Duntz Ltd; 2001:77-90.
40. Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain. 1997;120:299-315.
41. Pelletier D, Grenier D, Lu Y, Nelson SJ, Goodkin DE. Regional comparison of axonal damage in multiple sclerosis using whole supratentorial brain 3D spectroscopy imaging [abstract]. Proc Int Soc Magn Reson Med. 2001;2:985.
42. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol. 1995;38:901-909.
43. Sarchielli P, Presciutti O, Pelliccioli GP, et al. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain. 1999;122:513-521.
44. Husted CA, Goodin DS, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol. 1994;36:157-165.
45. Davies SE, Newcombe J, Williams SR, McDonald WI, Clark JB. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem. 1995;64:742-748.
46. Pan JW, Hetherington HP, Vaughan JT, Mitchell G, Pohost GM, Whitaker JN. Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T. Magn Reson Med. 1996;36:72-77.
47. Rooney WD, Goodkin DE, Schuff N, Meyerhoff DJ, Norman D, Weiner MW. 1H MRSI of normal appearing white matter in multiple sclerosis. Mult Scler. 1997;3:231-237.
48. van Walderveen MA, Barkhof F, Pouwels PJ, van Schijndel RA, Polman CH, Castelijns JA. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol. 1999;46:79-87.
49. Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain. 1996;119(Pt 3):715-722.
50. Gonen O, Moriarty DM, Li BS, Babb JS, He J, Listerud J, et al. Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations. Radiology. 2002;225:261-268.
51. Nijeholt GJ, van Walderveen MA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis: correlation between MRI parameters, clinical subtypes, and symptoms. Brain. 1998;121:687-697.
52. Filippi M, Horsfield MA, Hajnal JV, et al. Quantitative assessment of magnetic resonance imaging lesion load in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64(suppl 1):S88-S93.
53. Ciccarelli O, Brex PA, Thompson AJ, Miller DH. Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR. J Neurol. 2002;249:18-24.
54. Rosenfalck A, Andreassen S. Impaired regulation of force and firing pattern of single motor units in patients with spasticity. J Neurol Neurosurg Psychiatry. 1980;43:907-916.
55. Ng AV, Miller RG, Kent-Braun JA. Central motor drive is increased during voluntary muscle contractions in multiple sclerosis. Muscle Nerve. 1997;20:1213-1218.
56. Lee M, Reddy H, Johansen-Berg H, et al. The motor cortex shows adaptive functional changes to brain injury from multiple sclerosis. Ann Neurol. 2000;47:606-613.
57. Reddy H, Narayanan S, Amoutelis R, et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain. 2000;123:2314-2320.
58. Rocca MA, Falini A, Colombo B, Scotti G, Comi G, Filippi M. Adaptive functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with the extent of brain structural damage. Ann Neurol. 2002;51:330-339.
59. Pantano P, Iannetti GD, Caramia F, et al. Cortical motor reorganization after a single clinical attack of multiple sclerosis. Brain. 2002;125:1607-1615.
60. Filippi M, Rocca MA, Colombo B, et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage. 2002;15:559-567.
61. Filippi M, Horsfield MA, Tofts PS, Barkhof F, Thompson AJ, Miller DH. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain. 1995;118:1601-1612.
62. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis: US National MS Society Task Force. Ann Neurol. 1996;39:6-16.
63. Rossini PM, Caltagirone C, Castriota-Scanderbeg A, et al. Hand motor cortical area reorganization in stroke: a study with fMRI, MEG and TCS maps. Neuroreport. 1998;9:2141-2146.
64. Traversa R, Cicinelli P, Pasqualetti P, Filippi M, Rossini PM. Follow-up of interhemispheric differences of motor evoked potentials from the "affected" and "unaffected" hemispheres in human stroke. Brain Res. 1998;803:1-8.
65. Turton A, Wroe S, Trepte N, Fraser C, Lemon RN. Contralateral and ipsilateral EMG responses to transcranial magnetic stimulation during recovery of arm and hand function after stroke. Electroencephalogr Clin Neurophysiol. 1996;101:316-328.
66. van der Werf SP, Jongen PJ, Lycklama a Nijeholt GJ, Barkhof F, Hommes OR, Bleijenberg G. Fatigue in multiple sclerosis: interrelations between fatigue complaints, cerebral MRI abnormalities, and neurological disability. J Neuroi Sci. 1998;160:164-170.
67. Mainero C, Faroni J, Gasperini C, et al. Fatigue and magnetic resonance imaging activity in multiple sclerosis. J Neurol. 1999;246:454-458.
68. Kinkel PR. Fatigue in multiple sclerosis: reducing the impact through comprehensive management. International Journal of MS Care. 2000;2(suppl):3-10.
69. Vercoulen JH, Swanink CM, Zitman FG, et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet. 1996;347:858-861.
70. Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol. 1996;9:456-460.
71. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain. 1999;122:17-26.
72. Bo L NH, Vedeler C, Trapp BD, Mork SJ. Extensive cortical demyelination in multiple sclerosis brains [abstract]. Rev Neurol (Paris). 2000;156(suppl 3):S25.
73. Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain. 2002;125:2342-2352.